Breast Cancer 140124

January 03, 2017

Sponsor: Memorial Sloan Kettering Cancer Center

Number: 140124
This is an advanced Phase II study of various drugs to treat a metastatic form of breast cancer that produces the HER2 protein which provides messaging to cancer cells encouraging them to grow. It includes trastuzumab, gemcitabine and pertuzumab as a follow-up treatment to trastuzumab/pertuzumab therapy, and is meant to obstruct the HER2 messaging.

Who’s eligible: Patients must be women with metastatic HER2-positive breast cancer who were previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine. Patients may not have had more than three regimens of chemotherapy for metastatic cancer. If they already received gemcitabine, it may not have been combined with pertuzumab.
Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.

This study is for women age 18 and older.

Available at: Backus Hospital, The Hospital of Central Connecticut, Hartford Hospital.